Drug intelligence / Profile preview

ASP1948 + pembrolizumab

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ASP1948 + pembrolizumab is a combination of an investigational monoclonal antibody (ASP1948) with pembrolizumab, a marketed anti-PD-1 checkpoint inhibitor. ASP1948 targets an immune modulatory receptor and is being studied for its ability to enhance anti-tumor immune response. Pembrolizumab blocks PD-1, amplifying T-cell mediated anti-tumor activity. The combination is under investigation primarily in advanced solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, and breast cancer.

Other names: ASP1948 + Keytruda

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)NRP1 (Neuropilin-1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ASP1948 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP1948 + pembrolizumab.

Explore the full profile